MDCO: Medicines Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MDCO: Medicines Company

MDCO 84.90

0.0%

Jan 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike who wrote (83)	5/27/2003 9:49:08 AM
From: tuck	Read Replies (3) of 125

This is vague (no timeline given) but good news: >>PARSIPPANY, N.J.--(BUSINESS WIRE)--May 27, 2003-- The Medicines Company (Nasdaq: MDCO - News) today announced that "Chemilog", the second-generation manufacturing process for the bulk drug substance of Angiomax® (bivalirudin), has been approved by the U.S. Food and Drug Administration (FDA). The new process involves enhancements to early manufacturing steps to improve the efficiency of synthesizing bivalirudin, the active ingredient of Angiomax. Development of the new process was initiated in 1997 shortly after The Medicines Company acquired rights to Angiomax. Dave Stack, President and CEO of The Medicines Company stated, "Approval of the Chemilog process once again demonstrates our commitment to aggressive product development. We believe the Chemilog process allows us to scale up our manufacturing efficiently so that we can continue to meet customer demand for Angiomax. The timing of FDA approval allows us to immediately transition to Chemilog manufacturing as planned." << snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next